BioSpace

RevMed’s Rasonque shatters analyst estimates with $198M quarter

Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.

By BioSpace

1 min read
RevMed’s Rasonque shatters analyst estimates with $198M quarter
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights